RxSight (RXST) News Today $26.67 +2.30 (+9.44%) Closing price 04:00 PM EasternExtended Trading$26.46 -0.21 (-0.77%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BofA sees Bausch + Lomb IOL recall news as positive for RxSightMarch 27 at 7:43 PM | msn.comRxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 25 at 4:05 PM | globenewswire.comVitruvian Partners LLP Purchases New Position in RxSight, Inc. (NASDAQ:RXST)Vitruvian Partners LLP bought a new position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 144,300 shares of the company's stock, valued at approximately $4,961,000. RxSight accounts for approximaMarch 24 at 6:58 AM | marketbeat.comBank of America Cuts RxSight (NASDAQ:RXST) Price Target to $36.00March 24 at 1:49 AM | americanbankingnews.comThrivent Financial for Lutherans Increases Stake in RxSight, Inc. (NASDAQ:RXST)Thrivent Financial for Lutherans increased its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 53.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 352,626 shares of the company's stockMarch 23, 2025 | marketbeat.comBank of America Issues Pessimistic Forecast for RxSight (NASDAQ:RXST) Stock PriceBank of America decreased their target price on RxSight from $60.00 to $36.00 and set a "buy" rating on the stock in a report on Friday.March 22, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Sets New 1-Year Low Following Analyst DowngradeMarch 22, 2025 | americanbankingnews.comRxSight price target lowered to $36 from $60 at BofAMarch 21, 2025 | markets.businessinsider.comRxSight (NASDAQ:RXST) Sets New 12-Month Low Following Analyst DowngradeRxSight (NASDAQ:RXST) Hits New 52-Week Low Following Analyst DowngradeMarch 21, 2025 | marketbeat.comThe Analyst Verdict: RxSight In The Eyes Of 9 ExpertsMarch 21, 2025 | nasdaq.comStifel Nicolaus Issues Pessimistic Forecast for RxSight (NASDAQ:RXST) Stock PriceStifel Nicolaus cut their price target on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday.March 20, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Price Target Lowered to $28.00 at Stifel NicolausMarch 20, 2025 | americanbankingnews.comRxSight price target lowered to $28 from $33 at StifelMarch 20, 2025 | markets.businessinsider.comRxSight (RXST) Gets a Hold from Stifel NicolausMarch 20, 2025 | markets.businessinsider.comDoheny Asset Management CA Sells 26,210 Shares of RxSight, Inc. (NASDAQ:RXST)Doheny Asset Management CA decreased its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 40.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,300 shares of the company's stock after selling 26,21March 16, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Director Tamara Fountain Sells 7,000 SharesRxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the transaction, the director now directly owns 24,793 shares of the company's stock, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.March 14, 2025 | marketbeat.comVictory Capital Management Inc. Raises Holdings in RxSight, Inc. (NASDAQ:RXST)Victory Capital Management Inc. increased its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 4.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 271,978 shares of the company's stock after buying an additional 12,114March 14, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Telemark Asset Management LLCTelemark Asset Management LLC lifted its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 321,000 shares of the company'sMarch 13, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Shares Gap Up - Here's What HappenedRxSight (NASDAQ:RXST) Shares Gap Up - Time to Buy?March 12, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Reaches New 12-Month Low - Here's WhyRxSight (NASDAQ:RXST) Sets New 52-Week Low - Here's WhyMarch 11, 2025 | marketbeat.comAigen Investment Management LP Makes New $407,000 Investment in RxSight, Inc. (NASDAQ:RXST)Aigen Investment Management LP acquired a new position in RxSight, Inc. (NASDAQ:RXST - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,849 shares of the company's stock, valued at approximately $407,March 8, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Moderate Buy" by AnalystsShares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendationMarch 7, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Hits New 12-Month Low - What's Next?RxSight (NASDAQ:RXST) Hits New 52-Week Low - Should You Sell?March 5, 2025 | marketbeat.comSVB Wealth LLC Buys Shares of 76,816 RxSight, Inc. (NASDAQ:RXST)SVB Wealth LLC purchased a new position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 76,816 shares of the company's stock, valued at approximately $2,641,000. SVB WeMarch 2, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price TargetFebruary 28, 2025 | finance.yahoo.comMorgan Stanley Sticks to Their Buy Rating for RxSight (RXST)February 28, 2025 | markets.businessinsider.comRxSight (NASDAQ:RXST) Price Target Lowered to $40.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. decreased their price target on shares of RxSight from $62.00 to $40.00 and set an "overweight" rating for the company in a research note on Wednesday.February 27, 2025 | marketbeat.comRxSight price target lowered to $44 from $58 at BTIGFebruary 26, 2025 | markets.businessinsider.comRxSight (NASDAQ:RXST) Announces Earnings ResultsRxSight (NASDAQ:RXST - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%.February 26, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Shares Gap Down Following Weak EarningsRxSight (NASDAQ:RXST) Shares Gap Down on Disappointing EarningsFebruary 26, 2025 | marketbeat.comRxSight stock jumps as Q4 earnings beat expectations, guidance strongFebruary 26, 2025 | investing.comWells Fargo Reaffirms Their Hold Rating on RxSight (RXST)February 26, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for RxSight (RXST)February 26, 2025 | markets.businessinsider.comStifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $33.00Stifel Nicolaus dropped their target price on RxSight from $35.00 to $33.00 and set a "hold" rating on the stock in a research report on Wednesday.February 26, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Given New $35.00 Price Target at Wells Fargo & CompanyWells Fargo & Company reduced their price target on shares of RxSight from $40.00 to $35.00 and set an "equal weight" rating on the stock in a research report on Wednesday.February 26, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for RxSight (NASDAQ:RXST)Needham & Company LLC reiterated a "buy" rating and set a $43.00 price target on shares of RxSight in a research report on Wednesday.February 26, 2025 | marketbeat.comRxSight, Inc. (RXST) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comRxSight, Inc. (NASDAQ:RXST) Stock Holdings Boosted by New York State Common Retirement FundNew York State Common Retirement Fund lifted its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 32.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 294,051 shares of the company's stock after buying an additional 72,340February 26, 2025 | marketbeat.comRxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 GuidanceFebruary 25, 2025 | globenewswire.comWhat To Expect From RxSight Inc (RXST) Q4 2024 EarningsFebruary 25, 2025 | finance.yahoo.comRxSight Q4 2024 Earnings PreviewFebruary 24, 2025 | msn.comAlberta Investment Management Corp Cuts Position in RxSight, Inc. (NASDAQ:RXST)Alberta Investment Management Corp lowered its stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 51.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,972 shares of theFebruary 22, 2025 | marketbeat.comRxSight (RXST) to Release Earnings on WednesdayRxSight (NASDAQ:RXST) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664994)February 19, 2025 | marketbeat.comStifel Nicolaus Remains a Hold on RxSight (RXST)February 18, 2025 | markets.businessinsider.comBaillie Gifford & Co. Cuts Position in RxSight, Inc. (NASDAQ:RXST)Baillie Gifford & Co. lowered its holdings in RxSight, Inc. (NASDAQ:RXST - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 398,907 shares of the company's stock after selling 20,097 shares during the quarter. Baillie GiFebruary 18, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Trading Down 4.7% - Should You Sell?RxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?February 15, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendFebruary 10, 2025 | marketbeat.comInsider Stock Buying Reaches US$1.83m On RxSightFebruary 2, 2025 | finance.yahoo.comRxSight director sells $108,618 in common stockJanuary 27, 2025 | msn.comShweta Maniar Sells 3,519 Shares of RxSight, Inc. (NASDAQ:RXST) StockRxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Shweta Maniar sold 3,519 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the transaction, the director now owns 7,383 shares of the company's stock, valued at $227,913.21. This represents a 32.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.January 27, 2025 | marketbeat.com Remove Ads Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Media Mentions By Week RXST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXST News Sentiment▼0.040.78▲Average Medical News Sentiment RXST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXST Articles This Week▼115▲RXST Articles Average Week Remove Ads Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PROCEPT BioRobotics News iRhythm Technologies News Envista News TransMedics Group News Soleno Therapeutics News Enovis News LivaNova News NovoCure News Warby Parker News LeMaitre Vascular News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXST) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
